SkinHealth Systems Inc. Research and Development Expense
SkinHealth Systems Inc. (SKIN) reported Research and Development Expense of $1.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- SkinHealth Systems Inc. research and development expense for the quarter ending 2026-06-30 was $1.41M, a 12.47% increase year-over-year.
- SkinHealth Systems Inc. research and development expense for the quarter ending 2026-03-31 was $1.10M, a 10.42% increase year-over-year.
- SkinHealth Systems Inc. research and development expense for the quarter ending 2025-12-31 was $1.68M, a 37.56% increase year-over-year.
- SkinHealth Systems Inc. research and development expense for the quarter ending 2025-09-30 was $1.70M, a 53.25% increase year-over-year.
- SkinHealth Systems Inc. research and development expense for fiscal 2025 was $5.63M, a 10.61% decline from fiscal 2024.
- SkinHealth Systems Inc. research and development expense for fiscal 2024 was $6.30M, a 37.68% decline from fiscal 2023.
- SkinHealth Systems Inc. research and development expense for fiscal 2023 was $10.10M, a 19.64% increase from fiscal 2022.
- SkinHealth Systems Inc. research and development expense for fiscal 2022 was $8.44M, a 3.04% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-06 | $2.51M 10-Q · filed 2026-08-06 | $4.19M derived: sum of 3 quarters · filed 2026-08-06 | $5.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-07 | $2.78M derived: sum of 2 quarters · filed 2026-05-07 | $4.48M derived: sum of 3 quarters · filed 2026-05-07 | $5.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.38M derived: sum of 2 quarters · filed 2026-03-12 | $4.63M derived: sum of 3 quarters · filed 2026-08-06 | $5.63M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-06 | $2.95M derived: sum of 2 quarters · filed 2026-08-06 | $3.95M 10-Q · filed 2025-11-06 | $5.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.25M 10-Q · filed 2026-08-06 | $2.25M 10-Q · filed 2026-08-06 | $3.47M derived: sum of 3 quarters · filed 2026-08-06 | $4.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $998.00K 10-Q · filed 2026-05-07 | $2.22M derived: sum of 2 quarters · filed 2026-05-07 | $3.33M derived: sum of 3 quarters · filed 2026-05-07 | $4.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.33M derived: sum of 2 quarters · filed 2026-03-12 | $3.49M derived: sum of 3 quarters · filed 2026-03-12 | $6.30M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.11M 10-Q · filed 2025-11-06 | $2.27M derived: sum of 2 quarters · filed 2025-11-06 | $5.07M 10-Q · filed 2025-11-06 | $8.12M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $1.16M 10-Q · filed 2025-08-07 | $3.97M 10-Q · filed 2025-08-07 | $7.01M derived: sum of 3 quarters · filed 2026-03-12 | $8.85M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $2.81M 10-Q · filed 2025-05-08 | $5.85M derived: sum of 2 quarters · filed 2026-03-12 | $7.69M derived: sum of 3 quarters · filed 2026-03-12 | $10.57M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.88M derived: sum of 2 quarters · filed 2026-03-12 | $7.77M derived: sum of 3 quarters · filed 2026-03-12 | $10.10M 10-K · filed 2026-03-12 |
| 2023-09-30 | $1.84M 10-Q · filed 2024-11-12 | $4.72M derived: sum of 2 quarters · filed 2024-11-12 | $7.06M 10-Q · filed 2024-11-12 | $8.50M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-06-30 | $2.88M 10-Q · filed 2024-08-08 | $5.22M 10-Q · filed 2024-08-08 | $6.66M derived: sum of 3 quarters · filed 2025-03-12 | $8.83M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-03-31 | $2.34M 10-Q · filed 2024-05-09 | $3.78M derived: sum of 2 quarters · filed 2025-03-12 | $5.95M derived: sum of 3 quarters · filed 2025-03-12 | $8.55M derived: sum of 4 quarters · filed 2025-03-12 |
| 2022-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.61M derived: sum of 2 quarters · filed 2025-03-12 | $6.21M derived: sum of 3 quarters · filed 2025-03-12 | $8.44M 10-K · filed 2025-03-12 |
| 2022-09-30 | $2.17M 10-Q · filed 2023-11-14 | $4.77M derived: sum of 2 quarters · filed 2023-11-14 | $7.00M 10-Q · filed 2023-11-14 | $8.87M derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-06-30 | $2.60M 10-Q · filed 2023-08-09 | $4.83M 10-Q · filed 2023-08-09 | $6.71M derived: sum of 3 quarters · filed 2024-03-12 | $8.59M derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-03-31 | $2.23M 10-Q · filed 2023-05-10 | $4.11M derived: sum of 2 quarters · filed 2024-03-12 | $5.99M derived: sum of 3 quarters · filed 2024-03-12 | $8.97M derived: sum of 4 quarters · filed 2024-03-12 |
| 2021-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $3.75M derived: sum of 2 quarters · filed 2024-03-12 | $6.74M derived: sum of 3 quarters · filed 2024-03-12 | $8.20M 10-K · filed 2024-03-12 |
| 2021-09-30 | $1.88M 10-Q · filed 2022-11-09 | $4.87M derived: sum of 2 quarters · filed 2022-11-09 | $6.32M 10-Q · filed 2022-11-09 | $7.18M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $2.99M 10-Q · filed 2022-08-09 | $4.44M 10-Q · filed 2022-08-09 | $5.30M derived: sum of 3 quarters · filed 2023-03-01 | $5.88M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $1.45M 10-Q · filed 2022-05-10 | $2.31M derived: sum of 2 quarters · filed 2023-03-01 | $2.89M derived: sum of 3 quarters · filed 2023-03-01 | $3.49M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $860.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.44M derived: sum of 2 quarters · filed 2023-03-01 | $2.03M derived: sum of 3 quarters · filed 2023-03-01 | $3.41M 10-K · filed 2023-03-01 |
| 2020-09-30 | $577.00K 10-Q · filed 2021-11-12 | $1.17M derived: sum of 2 quarters · filed 2021-11-12 | $2.55M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $597.00K 10-Q · filed 2021-08-13 | $1.97M 10-Q · filed 2021-08-13 | ||
| 2019-12-31 | $4.61M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |